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Abstract: Multiple, epizootic outbreaks of feline panleukopenia (FPL) caused by feline parvovirus
(FPV) occurred in eastern Australia between 2014 and 2018. Most affected cats were unvaccinated.
We hypothesised that low population immunity was a major driver of re-emergent FPL. The aim of
this study was to (i) determine the prevalence and predictors of seroprotective titres to FPV among
shelter-housed and owned cats, and (ii) compare the prevalence of seroprotection between a region
affected and unaffected by FPL outbreaks. FPV antibodies were detected by haemagglutination
inhibition assay on sera from 523 cats and titres ≥1:40 were considered protective. Socioeconomic
indices based on postcode and census data were included in the risk factor analysis. The prevalence
of protective FPV antibody titres was high overall (94.3%), even though only 42% of cats were
known to be vaccinated, and was not significantly different between outbreak and non-outbreak
regions. On multivariable logistic regression analysis vaccinated cats were 29.94 times more likely
to have protective FPV titres than cats not known to be vaccinated. Cats from postcodes of
relatively less socioeconomic disadvantage were 5.93 times more likely to have protective FPV
titres. The predictors identified for FPV seroprotective titres indicate targeted vaccination strategies
in regions of socioeconomic disadvantage would be beneficial to increase population immunity.
The critical level of vaccine coverage required to halt FPV transmission and prevent FPL outbreaks
should be determined.
Keywords: Carnivore protoparvovirus; feline parvovirus; feline panleukopenia; haemagglutination
inhibition; seroprevalence
1. Introduction
Feline panleukopenia (FPL), caused by Carnivore protoparvovirus 1 (Order Ortervirales, Family
Parvoviridae, Subfamily Parvovirinae), is characterised by severe enteritis and immunosuppression and
has high morbidity and mortality. Feline parvovirus (FPV) causes 95% of cases, with the remaining 5%
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caused by canine parvovirus (CPV), including the antigenic variants CPV-2a, -2b, and 2c, also known
as “CPV-2a-like” viruses [1].
In Australia FPL has been encountered only sporadically since the mid-1970s when the use of
effective vaccines became widespread. Between 2014 and 2018, FPL re-emerged in eastern Australia,
causing multiple epizootic outbreaks with high mortality predominantly among shelter-housed cats [2].
FPV was identified as the causative agent of the first outbreak in 2014 in the state of Victoria [2].
Outbreaks in New South Wales (NSW) first occurred in 2016 and were caused by a different and
distinctive FPV strain, ruling out geographic spread from Victoria. Most affected cats were unvaccinated,
or vaccination history was unknown; hence low population immunity was hypothesised to be a major
driver of FPL re-emergence [1,2].
Serum antibody titres to FPV, determined using virus neutralisation (VN) or haemagglutination
inhibition (HI) assays or ELISAs (laboratory-based or point-of-care), are used to predict protection from
disease [3–6]. A cut-off ≥1:40 is used widely to define the minimum HI titre that confers serological
protection, but a range of cut-offs from 0 to ≥1:80 have been reported [3,4,7–9].
A single previous study of the seroprevalence of FPV antibodies in Australian cats (Felis catus)
undertaken in 1981 and involving 92 unowned, free-living cats in south-eastern Australia, found a
seroprevalence of 79%, suggesting widespread exposure to FPV [10]. FPV seroprevalence data among
shelter-housed cats or owned cats in Australia have not been reported previously. Factors associated
with FPV seropositivity in other regions include previous vaccination [11], increasing age, being owned,
and being desexed [8,9,12,13].
The aim of this study was to determine (i) FPV seroprevalence and predictors of seropositivity
among shelter-housed and owned cats, and (ii) whether seroprevalence differed in these two cohorts
between an outbreak location in eastern Australia (Sydney) and a region with no recent history of FPL
outbreaks in western Australia (Perth).
2. Materials and Methods
2.1. Study Populations
Blood samples were collected from four groups of cats: (i) owned and (ii) shelter-housed cats from
Sydney, NSW, a region in which recurrent FPL season outbreaks have been occurring since December
2016 [2]; and (iii) owned and (iv) shelter-housed cats from Perth, Western Australia (WA), where no
FPL outbreaks have been reported in recent decades. Blood samples were collected from a single large
shelter in Perth and from three smaller shelters in Sydney. Blood samples were collected from owned
cats presenting for veterinary consultations collected from seven veterinary hospitals in Sydney and
from two veterinary hospitals in Perth. In Sydney, four of the veterinary hospitals included were in
close proximity to the previously reported outbreaks and were participating in a subsidised vaccination
and desexing scheme offered by a charitable feline organisation. A power analysis was performed to
determine the number of cats to be sampled. Based on an estimated minimum seroprevalence of 15%
to 40% among shelter-housed cats, and 50% to 70% among owned cats, the minimum total sample size
required to detect a difference in seroprevalence between these groups, with confidence set at 95%,
significance of p < 0.05, and power ≥80%, was 200 cats overall [14]. The sample size required for risk
factor analysis an odds ratio of 1.5 to be detected with 95% confidence and 40% precision assuming
a 20% prevalence of the risk factor in cats with non-protective antibody titres, and a minimum ratio
of cats with protective titres to cats with non-protective titres of 1.5 was 142 cats with non-protective
titres [15], which would be achieved by sampling 400 cats overall (100 in each group).
2.2. Sampling and Data Collection
Whole blood (1–3 mL) was collected via jugular venepuncture and serum was separated and
stored frozen at −20 ◦C for up to 4 weeks, then transferred for storage at −80 ◦C until batch testing.
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Prospective sampling was performed from June 2018 to July 2019. Additionally, 35 stored sera collected
from July to August 2015, from owned cats in Perth (non-outbreak region) were included.
Data collected for each cat sampled included age, sex, desexing status, breed, location (post code),
reason for presentation (health check, injured or unwell, vaccination, desexing, stray, other), time in
possession of owner or shelter, other dogs or cats in the household (yes or no), health status (healthy,
defined as fit to vaccinate, sick or injured), current medications, feline leukemia virus (FeLV) antigen
status, feline immunodeficiency virus (FIV) antibody status, FPV vaccination status, time since last
vaccination (<6 months ago, 6–12 months ago, 1–3 years ago, >3 years ago and type of vaccination
(attenuated or inactivated). The study was approved by the University of Sydney Animal Care and
Ethics Committee, Approval No. 2017/1218.
2.3. Haemagglutination Inhibition (HI) Serology
FPV antibody titres were determined by HI assays using sera after complement inactivation,
as previously described, with minor modifications [16,17]. Briefly, serum was diluted in
phosphate-buffered saline (PBS) pH 5.6 and mixed with an equal amount v/v of undiluted porcine red
blood cells (RBC), then centrifuged after overnight incubation at 4 ◦C, at 800× g for 5 min at 4 ◦C and
the supernatant was harvested. HI assays were performed in 96-well V-bottom plates (Nuova Aptaca,
Canelli-AT, Italy) using 25 µL of diluted sera mixed with 25 µL of an FPV suspension containing 10
haemagglutinating units (FPV field strain 20/05), and doubling dilutions from 1:10 to 1:2560. Plates
were incubated at room temperature for 1 h, then at 4 ◦C for 30 min, after which 50 µL of a solution
containing 0.1% porcine RBC suspension and 2% foetal bovine serum (Mediatech, Inc., Manassas, VA,
USA) in PBS pH 7.2 were added to each well. Plates were read after overnight incubation at 4 ◦C. A
titre of ≥1:40 was considered protective.
2.4. Statistical Analysis
Descriptive analysis was performed by creating frequency distributions for categorical variables
and estimating medians for continuous variables. Statistical analyses were performed using the
software package IBM SPSS Statistics v24. For univariable analysis of the association between FPV
protection status and categorical predictor variables, Chi-squared tests of association were used, with a
p-value set at 0.05 for statistical significance and a protective titre was defined as an HI titre ≥1:40 [4,18].
Seroprevalence confidence intervals (95%) were calculated using the Clopper–Pearson exact test.
Socioeconomic data were sourced from the Australian Bureau of Statistics Socio-Economic Indexes
for Areas (SEIFA) data cube from 2011 based on postcode and published by the Australian Bureau of
Statistics in 2013, and the index of relative socio-economic disadvantage (IRSD), the index of relative
socio-economic advantage and disadvantage (IRSAD), the index of economic resources (IER), and the
index of education and occupation (IEO) [19] were extracted. Index values for each cat included in the
study were based on its reported postcode. The association between each of the four indices and FPV
protection status (protective vs. non-protective titre) was assessed using Mann–Whitney U tests, with
a p-value of 0.05 used for statistical significance.
A multivariable logistic regression model was fit to the data using predictors significantly (p < 0.05)
associated with FPV protection status analysis. A separate logistic regression analysis was performed
using SEFIA variables included as categorical variables (above median vs. median or below median).
The association between FPV titre and vaccination status was assessed with Kruskal–Wallis one-way
analysis of variance, with a p-value of 0.05 used for statistical significance.
3. Results
3.1. Animals
A total of 523 cats were included in the study comprising 282 cats from Sydney (outbreak-region)
and 241 cats from Perth (non-outbreak region). The geographic origins of cats sampled in the study are
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shown in Figure 1. Of the 523 cats, 234 were shelter-housed and 289 were owned. The median age of
cats overall was 1.75 years (range: 7 weeks to 21 years). The median age of cats within each group was
1 year and 1.1 years for Sydney owned and shelter-housed cats, respectively and 10 years and 1 year
for Perth owned and shelter-housed cats, respectively. The median age of cats overall from Sydney
and Perth was 1 year and 3.5 years, respectively.
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Figure 1. Geographic origin of samples collected in this study. Samples collected from shelter-housed
cats are represented by blue dots, and samples from owned cats are represented by red dots. The size of
the dots is proportional to the number of samples collected from one postcode area. The postcode areas
sampled are shaded in beige. Owned (a) and shelter-housed (b) cats in the outbreak region (Greater
Sydney); owned (c) and shelter-housed (d) cats in the non-outbreak region (Greater Perth).
Of cats from Sydney, 29% of owned and 47% of shelter-housed cats were vaccinated; of cats from
Perth, 19% and 78% of owned and shelter-housed cats, respectively were vaccinated. Overall, 37.5%
and 48.1% of cats were vaccinated from Sydney and Perth, respectively. Other categorical data are
shown in Table 1.
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Table 1. Descriptive and univariable analysis of risk factors potentially associated with a protective
feline parvovirus serum haemagglutination antibody titre (≥1:40) for 523 shelter-housed and owned
cats tested from Sydney and Perth.
Variable Category Total No.
Protective FPV
Titre 95% CI X2-Value p-Value 1
No. %
Group
Perth owned 117 112 95.7 90.4–96.8
11.733 0.008
Perth shelter 124 115 92.7 86.7–96.6
Sydney owned 172 156 90.7 90.9–96.7
Sydney shelter 110 110 100 96.7–100
Shelter vs. Owned
Shelter 234 225 96. 92.8–98.2
2.798 0.094Owned 289 268 92.7 89.1–95.5
Location
Perth 241 227 94.2 90.4–96.8
0.004 0.947Sydney 282 266 94.3 90.9–96.7
Age
<1 year 205 188 91.7 87.05–95.1
4.154 0.1251–8 years 232 222 95.7 92.2–97.9
>8 years 86 83 96.5 90.1–99.3
Sex
Male 241 224 93 89–95.8
2.202 0.138Female 250 240 96 92.8–98.1
Desexing Status
Desexed 275 263 95.6 92.5–97.7
0.755 0.686Intact 195 183 93.9 89.5–96.8
Unknown 19 18 94.7 74.0–99.9
Breed
Domestic 418 403 96.4 94.2–98.0
0.087 0.087Non-domestic 53 50 94.3 84.4–98.9
Outdoor Access
Indoors only 99 91 91.9 84.7–96.5
0.788 0.375Outdoor access 253 239 94.5 90.9–96.9
Dogs in the House No 97 96 99.0 94.4–100 0.519 0.471Yes 50 50 100 92.9–100
Source
Breeder/Pet shop 51 48 94.1 83.8–98.8
4.435 0.109Shelter/Stray 275 259 94.2 90.7–96.6
Other 108 107 99.1 95.0–100
Health Status
Healthy 417 396 95.0 92.4–96.9
0.085 0.770Sick/Injured 71 68 95.8 88.1–99.1
Vaccination Status
Vaccinated 218 217 99.5 97.5–100
17.617 <0.001Unvaccinated or
Unknown 305 276 90.5 86.6–93.5
Vaccination Type
MLV only 114 113 99.1 95.2–100
0.336 0.846Inactivated only 18 18 100 81.5–100
Both 20 20 100 83.2–100
Time Since Last
Vaccination
<6 months 22 21 95.5 77.16–99.9
1.651 0.199
6–12 months 126 126 100 97.1–100
1–3 years 38 38 100 90.8–100
>3 years 22 22 100 84.6–100
Unknown 10 10 100
Medications
No 446 419 94.0 91.3–96.0
0.565 0.452Yes 77 74 96.1 89.0–99.2
FeLV Antigen
Status
Negative 82 82
100 95.6–100 n/a n/aPositive 0 0
FIV Antibody
Status
Negative 105 104 99.1 94.8–100
0.23 0.631Positive 24 24 100 85.8–100
1 Significant p-values (<0.05) are in bold text; FPV: feline parvovirus; FeLV: feline leukemia virus; FIV: feline
immunodeficiency virus; MLV: modified live virus.
3.2. Seroprevalence and Variables Associated with a Protective FPV Titre
Overall, 493 of the 523 cats (94.3%) had protective FPV antibody titres. The frequency distribution
of FPV HI titre results is shown in Figure 2. There was a significant difference in the magnitude
of FPV titres between vaccinated cats and cats that were unvaccinated or of unknown vaccination
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status (p < 0.001). Among seropositive cats, the median HI titre was 1:160 for unvaccinated/unknown
vaccination status cats and 1:640 for vaccinated cats (p < 0.001).
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For the un variable analysi , cats of unknow vaccin ion status (n = 200) and unv ccinated
cats (n = 105) were con idered as one group. There was o signifi ant difference in the presence
f FPV protective titres be ween cats f unknown vaccin tion status (91%; CI 86.1 %–94.58%) and
unvaccinated cats (89.5%; CI 82.01%–94.65%; X2 = 0.1744, p = 0.6762). In the univariable analysis,
factors significantly associated with a protective FPV titre were study group, vaccination status (Table 1),
and three of the four SEIF s (IRSD p = 0.001; IRSAD p = 0.001; IEO p = 0.002).
A multivariable logistic regression analysis was performed to predict FPV protection status.
Using a stepwise logistic regression model fit to the significant variables in the univariable analysis,
group, and vaccination status, a large standard error for the Sydney shelter group indicated that
the variable “group” was problematic to include in this model. A more stable model was achieved
using the variables of ownership (owned, shelter-housed) and vaccination status (vaccinated vs.
unvaccinated/unowned). The model adequately fit the data (Hosmer–Lemeshow, p = 0.077 and
Nagelkerke r2 value = 0.164). In this model the predictors of having a protective titre were being
vaccinated (odds ratio (OR) = 29.94) and being a shelter-housed cat (OR = 2.69) (Table 2).
Table 2. Results of logistic regression analysis using model of best fit containing the variables:
vaccinated, Sydney (outbreak) location, and shelter-housed.
B SE Wald df p-Value OR 95% CI
Vaccinated 3.293 1.024 10.346 1 0.001 29.94 3.62–200.4
Shelter-Housed 0.988 0.416 5.635 1 0.018 2.685 1.19–6.07
Constant 1.140 0.407 7.843 1 <0.001 3.128 –
B: beta coefficient; SE: standard error; df: degrees of freedom; OR: odds ratio; CI: confidence interval.
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For logistic regression analysis of SEIFA data, when re-categorised as above median vs. median
or below median, the IRSD was the best predictor of protective status and cats from postcodes with
above median index of disadvantage (relatively less disadvantaged) were 5.93 times more likely to
have protective FPV titres (Table 3). The model adequately fit the data (Hosmer–Lemeshow, p = 0.999
and Nagelkerke r2 value = 0.080)
Table 3. Results of logistic regression analysis using model of best fit to analyse the index of relative
socio-economic disadvantage (IRSD).
B SE Wald df p-Value OR 95% CI
IRSD 1.780 0.629 7.995 1 0.005 5.928 1.73–20.35
Constant 2.369 0.240 97.486 1 0.000 10.684 –
B: beta coefficient; SE: standard error; df: degrees of freedom; OR: odds ratio; CI: confidence interval; IRSD: index of
relative social disadvantage.
4. Discussion
The prevalence of protective FPV antibody titres was surprisingly high, exceeding 94% in cats
studied. Among vaccinated cats the high prevalence of seroprotection (99.5%) was not unexpected,
since FPV vaccines are highly effective in inducing long-lasting humoral immunity [4]. A similarly high
FPV seroprevalence among vaccinated cats (97%–98%) was reported in North America in 2004, and in
Austria in 2016 [20] (Table 4). However, high seroprevalence among vaccinated cat populations is not
universal. For example, an investigation of 350 cats in Germany found that 23% of cats that had received
FPV vaccinations in accordance with current global vaccination guidelines had no detectable serum
antibodies [8,11]. In that study, in addition to vaccination status, risk factors for being seronegative
were comorbid disease and glucocorticoid administration.
Table 4. Seroprevalence of protective serum antibody titres against FPV in domestic cats from different
geographic regions.
Year of
Sampling Country No. Cats Origin of Cats
Proportion Known to
Be Vaccinated (%)
FPV
Seroprevalence
(%)
Reference
1981 Australia 92 stray/feral 0 79 [10]
1989 UK 45 free-ranging farmcats 0 96 [20]
1997 Vietnam (North) 69 unowned 0 54 [21]
1998 Vietnam (South) 50 unowned 0 44 [22]
1998–2000 Saudi Arabia 13 feral 0 8 [23]
2004 Ecuador 52 owned/feral 0 67 [24]
2005 USA (Florida) 61 feral 0 33 [25]
2007 France 469 owned/stray 0 25 [12]
2010 USA (Florida) 347 shelter 0 40 [9]
2013 Russia 60 owned 0 45 [26]
2017–2018 Italy 151 stray 0 46 [13]
1998–2001 Costa Rica 97 owned 17 93 [27]
2001 USA (Colorado) 276 owned U 69 [3]
2001 Guatemala 30 owned 27 50 [28]
2003 USA and Canada 272 owned 100 98 [7]
2011–2012 Germany 350 owned 81 71 [8]
2012–2014 Germany 112 owned 64 64 [29]
2016 Austria 92 owned 100 97 [19]
U: unknown.
We identified that a history of FPV vaccination was a strong predictor of protective FPV antibody
titres, and the OR of 29.9 among vaccinated cats, was similar to that found in the German study, in
which the OR for vaccinated cats having protective FPV titres was 24.8 [8].
The high proportion of seroprotective titres among cats that were unvaccinated or of unknown
vaccination status was unexpected. Although it is likely that some cats of unknown vaccination status
were in fact vaccinated, there was no significant difference in seroprotection prevalence between
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this group and unvaccinated cats. Serosurveillance of unvaccinated domestic cats in other countries
revealed an FPV seroprevalence ranging from 8% to 96%, although <50% of cats were seropositive in
7 of 10 studies [9,12,13,21–27] (Table 4). We used a cut-off HI titre of 1:40 to define seroprotection to
allow comparison with the majority of published studies. The WSAVA vaccination guidelines panel
considers that the presence of a serum antibody, regardless of titre, is protective [11]. Using that
approach would have made little difference to our results, since only five cats had HI titres above zero
but less than 1:40.
Our results indicate that cats in Australia are commonly exposed to Carnivore protoparvovirus 1
in the field. Unvaccinated cats could have had environmental exposure to field or vaccine strains
of FPV or CPV. Cats are primarily exposed to FPV through contact with fomites, since this small
non-enveloped virus is extremely environmentally resilient and capable of persisting for >12 months
in favourable conditions [30,31]. Environmental contamination is largely due to faecal shedding of
the virus by infected cats, who shed the virus at very high titres for several weeks post-infection.
Attenuated vaccine virus strains are also shed in the faeces of vaccinated cats subsequent to replication
in the gut [2,32].
The extent to which exposure to CPV in cats provides protection against FPV infection has not
been investigated. CPV is antigenically similar to FPV, since these viruses only differ by several amino
acid residues in the viral capsid [33]. In experimental studies where cats were inoculated with CPV-2c
or CPV-2a orally, all cats developed FPV neutralising (VN) antibody titres, but of a lower magnitude
than VN titres to CPV, suggesting that immunity to FPV induced by CPV would be shorter in duration
than that induced by FPV [34]. Similarly, sera from cats immunised with attenuated FPV vaccines
neutralise CPV, although neutralising antibody titres are two- to eight-fold lower than those induced
by CPV, consistent with a shorter duration of immunity [5,35]. Interestingly, seropositive cats that
were unvaccinated or of unknown vaccination status in our study had three-fold lower median HI
titres than vaccinated cats. This could be due to a number of factors, including exposure to CPV but
not FPV, or a decline in FPV titre over time after initial exposure in unvaccinated cats in contrast to
vaccinated cats, which may have been re-vaccinated repeatedly over time. In cats that develop FPL,
exposure to field strains of parvoviruses by natural infection often induces higher VN or HI titres
than those induced after vaccination with a homologous strain [34,36]. Whether this is true for cats
subclinically infected with FPV is not known. We did not find an association between the presence
of dogs in the household and FPV seropositivity, although this is not surprising since exposure to
parvoviruses is often indirect. Future investigations to determine CPV- and FPV-specific antibody
titres simultaneously are warranted in order to better understand the dynamics of the role of exposure
to heterologous parvoviruses in FPV immunity among unvaccinated cats. In addition, or alternatively,
the parvoviral strains that cats have been exposed to can be determined by molecular sequencing of
persistent episomal parvoviral DNA in blood monocytes post-infection. In two of three studies that
used this technique in healthy seropositive cats from Italy and Vietnam, exposure to CPV was found to
be as, or more, frequent than to FPV [37–39].
The high rate of FPV seropositivity among cats not known to be vaccinated also indicates that
most infections were likely subclinical or caused only mild disease. The development and severity of
FPL in naïve cats is dependent on the interplay of multiple host factors (e.g., age, immune status) and
viral factors (e.g., inoculating dose), as well as the presence, in some cases, of co-pathogens including
intestinal parasites and other enteric viruses (e.g., bocaviruses) [40,41]. Since FPV is profoundly
immunosuppressive in cats, opportunistic pathogens, such as bacteria and fungi, can also contribute to
the development of severe clinical disease [42,43]. The role of co-pathogens, if any, in the Australian
FPL outbreaks, has not been investigated.
Contrary to our expectations, we did not find a significant difference in FPV seroprevalence
between outbreak and non-outbreak regions. The high rate of immunity in the outbreak population
tested may reflect “boosting” of population immunity among unvaccinated cats due to widespread
exposure to FPV in the field, since sera were collected one to two years after the first epizootic outbreaks
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occurred in Sydney. Supporting this, the seroprevalence in the outbreak population was high despite
the overall proportion of cats known to be vaccinated (37.5%) being lower than that of the non-outbreak
population (48%).
Unlike several other studies in which FPV seropositivity was associated with age >6 months or
age >1 year, reflecting an increasing likelihood of exposure over time, and especially within the first
year of life, we did not find an association with age [9,12,13].
The significant difference in seroprevalence among the four groups of cats detected in univariable
analysis was likely influenced by the different vaccination proportions among these groups. Owned
cats in Sydney were younger than those in Perth because we targeted veterinary clinics in close
proximity to the previous FPL outbreaks that were enrolling cats for subsidised desexing programs in
the outbreak region.
We could not include group in the multivariable analysis together with vaccination status because
of the large standard error (SE) associated with the Sydney shelter group, likely a consequence of the
uniform presence of protective titres in this study group. Another potential limitation of our study
was that the number of seronegative results was smaller than expected, which might have limited our
ability to identify significant predictors of seropositivity in logistic regression analyses. The finding
that shelter-housed cats were 2.65 times more likely to have protective FPV titres than owned cats may
have been influenced by differences in their exposure history.
Our finding that cats from postcodes of relatively less disadvantage were 5.93 times more likely
to have protective FPV titres is useful to inform strategies to achieve more homogeneous immunity
to FPV in the cat population, such as the locations and frequency of community companion animal
vaccination and pet health educational events provided by veterinary professional organisations and
animal charities. The IRSD used in this study is based on measures of wealth and income, including
household income, employment status, and level of education obtained from census data [19].
Based on FPV seroprevalences of 68.5% to 70.6% among owned populations of cats, it has been
suggested that epizootic outbreaks will not occur when the seroprevalence is >70% [11,40]. However,
the critical level of vaccine coverage required to prevent FPL outbreaks is unknown, since the basic
reproduction number (R0) of FPV (i.e., the number of new cases of infection generated by the first
infectious individual in a completely susceptible population), has not been modelled for Carnivore
protoparvovirus 1 from outbreak data [44]. Simplistically, the critical level of vaccine coverage, or the
fraction of the population that is required to be immunised to halt transmission of a pathogen within
a population, can be calculated as 1 − 1/R0 [44]. For pathogens with a high R0, the critical level of
vaccine coverage is very high and outbreaks can occur with relatively small fluctuations in population
immunity, even though the vast majority of the population is immune [45]. Disease outbreaks can occur
when inhomogeneous vaccine coverage results in susceptible pockets of the population occurring in
an otherwise protected population.
While vaccination is undoubtedly the most effective strategy to protect a cat against FPL,
administration of FPV vaccines to seropositive cats is unnecessary, ineffective in boosting immunity,
and has the potential for adverse effects [46]. FPV antibody titre testing is being increasingly used by
veterinarians to determine the timing of vaccine administration in owned cats. Point-of-care (POC)
tests with high positive predictive values (PPV) are desirable and enable the decision to vaccinate
to be made during the same consultation as testing. POC tests with high PPV are available for FPV
titre testing in cats, and since PPV increases with seroprevalence, use of these tests among similar
populations of Australian cats to those tested here, would be unlikely to result in seronegative animals
not being vaccinated, since the likelihood of incorrect identification of a cat as being seropositive would
be very low [6].
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